Pembrolizumab-Induced Sarcoid-Like Reaction in a Patient With Lung Cancer

Cancer is not only the leading cause of mortality and morbidity but also poses a major economic burden. Until recently, onco-immunotherapy has dramatically changed the landscape of cancer treatment. For example, an inhibitor of programmed cell death (PD-1) plays a vital role by potentiating effective immune-mediated destruction of tumor cells. However, the spectrum of immune-related adverse events especially granulomatous sarcoid lesions has been recognized too. Such lesions involve the dermis and subcutaneous tissue (panniculitis) and lymph nodes. Herein we are presenting a case report of a patient, who developed a sarcoid-like reaction after treatment with pembrolizumab.